Characteristics of Patients with Crohn's Disease With or Without Perianal Fistulae in the CorEvitas Inflammatory Bowel Disease Registry.

"Declarations Conflict of interestThis study design and conduct were the result of a collaborative effort between CorEvitas, LLC, and Boehringer Ingelheim. YF, SDA, and WCV are employed by Boehringer Ingelheim. PCM, JCJ, and MMC are employed by CorEvitas, LLC. RWS has received consultancy fees for AbbVie, Janssen, Merck, Takeda, Eli Lilly, Gilead, Exact Sciences, and CorEvitas, LLC, and has received investigator-initiated research support from AbbVie. Data availabilityThe CorEvitas (formerly Corrona) LLC dataset is based on a large North American multicenter study adhering to a number of institutional review boards, with complex logistics. Patients did not provide consent to raw data sharing during the data collection for this purpose, and the CorEvitas data-sharing policies do not permit raw data sharing for this purpose. An aggregated limited dataset from the current approved analyses is available to qualified investigators with an approved protocol. Data requests may be sent to CorEvitas, LLC, represented by Dr. Jeffrey D. Greenberg MD, MPH, NYU School of Medicine, New York, NY, e-mail jgreenberg@corevitas.com. Conflict of interest This study design and conduct were the result of a collaborative effort between CorEvitas, LLC, and Boehringer Ingelheim. YF, SDA, and WCV are employed by Boehringer Ingelheim. PCM, JCJ, and MMC are employed by CorEvitas, LLC. RWS has received consultancy fees for AbbVie, Janssen, Merck, Takeda, Eli Lilly, Gilead, Exact Sciences, and CorEvitas, LLC, and has received investigator-initiated research support from AbbVie."

"Funding This study was sponsored by CorEvitas, LLC, and the analysis was funded by Boehringer Ingelheim. Access to study data was limited to CorEvitas, and CorEvitas statisticians completed all the analysis; all authors contributed to the interpretation of the results. The CorEvitas IBD Registry has been supported through contracted subscriptions in the last two years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Chugai, Eli Lilly and Company, Genentech, Gilead, GlaxoSmithKline, Janssen, Novartis, Ortho Dermatologics, Pfizer, Inc., Regeneron, Sanofi, Sun, and UCB."